Deze website maakt gebruik van cookies. We gebruiken cookies om instellingen te onthouden en je bezoek soepeler te laten verlopen. Daarnaast gebruiken we ook cookies voor de verbetering van de website en het verzamelen en analyseren van statistieken. Lees meer over cookies

Home
Home
Harm van Tinteren

Harm van Tinteren

Hoofd Trial en Datacentrum

Trial- en Datacentrum

Telefoon 31 65 01 73 064

E-mail H.vanTinteren@prinsesmaximacentrum.nl

Pediatric renal tumor epidemiology
- jan. 2023
- Jaime, Libes, et al
- Pediatric Blood and Cancer
Patterns of Hearing Loss in Irradiated Survivors of Head and Neck Rhabdomyosarcoma
- dec. 2022
- Franciscus A., Diepstraten, et al
- Cancers
Incidence and survival of paediatric renal tumours in the Netherlands between 1990 and 2014
- nov. 2022
- Maya, Schulpen, et al
- European Journal of Cancer
Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer
- nov. 2022
- Sonja B., Vliek, et al
- European Journal of Cancer
Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer
- okt. 2022
- Erik, van Dijk, et al
- International Journal of Cancer

Bekijk alle publicaties

Harm van Tinteren

Publicaties

Pediatric renal tumor epidemiology

Patterns of Hearing Loss in Irradiated Survivors of Head and Neck Rhabdomyosarcoma

Incidence and survival of paediatric renal tumours in the Netherlands between 1990 and 2014

Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer

Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer